NewGen BioPharma Corp. (NEWG)

[Big Brother]

I'm not really a pharma guy but this does look pretty interesting.

https://www.linkedin.com/in/navdeepjaikaria

Summary
Dr. Navdeep Jaikaria is the Founder and Chairman of NewGen BioPharma, a U.S. based global company focused on using proprietary nanotechnologies to generate novel, superior and cost-effective pharmaceuticals. He has been at the forefront of cutting-edge biotechnologies in his various professional roles and has trained at some of the finest institutions in India and the US and with leading scientists of his times. Dr. Jaikaria has successfully used his scientific acumen and expertise to consistently identify and value ground-breaking therapies and biopharma technologies as successful investment opportunities in his Wall Street career spanning over 8 years. He has a broad knowledge base in the health care industry. During his career, he has successfully assembled & managed competent teams of scientific experts and business professionals in high-pressure, productivity-focused environments.

Navdeep’s industry and investment perspectives have been widely cited in the print & broadcast media including The Wall Street Journal, Financial times, Businessweek, Forbes. He has periodically appeared as a guest commentator on CNNfn, CNBC and CNN India. He has provided policy input to the US senate health committee on biodefense.

Navdeep was named as one of the five best stock-pickers in Biotechnology in the Wall Street Journal's annual "Best on the Street" Analysts survey in 2007. He was consistently ranked as a top analyst and as high as #3 by Starmine in 2006. Navdeep won many academic awards throughout his career, including the Martha Lucas Pate, Ph.D. Memorial Award for academic excellence & leadership at the New York Medical College & the Naval Research Scholarship to conduct research at Stanford University. He was ranked #2 overall at the All India Institute of Medical Sciences and was awarded the prestigious National Talent Search Scholarship – the highest scholastic award in India after high school.

Navdeep sits on Non-for-profit and Corporate Boards.

Specialties: Global biopharmaceutical due diligence, Finance, Business Development, M&A , Strategic & Investment Advisory

Experience
Founder & Chairman
NewGen BioPharma Corp.
December 2010 – Present (6 years 1 month)
Dr. Jaikaria Founded NewGen BioPharma Corp., US and its Indian subsidiary, New India BioPharma in 2010. Dr. Jaikaria has successfully raised multi-million dollars in investment capital and has transformed NewGen into a commercial stage company with a marketed product and a strong pipeline of products in various stages of clinical and pre-clinical development. NewGen BioPharma Corporation is a specialty pharma company that is developing and commercializing enhanced pharmaceuticals through reformulating approved products using proprietary Micellar Nano Particulate [MNP] technology platform. The MNP platform improves the solubility and bioavailability of difficult to formulate and deliver drugs that have low water solubility and poor bioavailability.

MNP platform is one of the three nanotechnology platforms that have a drug approved by the FDA. Nano-formulations confer significant advantages to drugs leading to an improvement in their bioavailability in the blood, improvement in safety, efficacy, dosage reductions and elimination of fed-fast variability – all leading to improved clinical outcomes and better patient compliance. In addition MNP platform can deliver traditional drugs delivered as oral pills through the skin. A striking attribute of the topical MNP preparations is that the residence time of the Active Pharmaceutical Ingredient (API) is increased in the skin, thereby reducing the dose or reducing the number of applications per day. This attribute also makes MNP technology very desirable to address a huge unmet medical need – to deliver drugs effectively and selectively to the skin or in a local manner to joints etc. We also have an entire line of MNP based cosmeceutical products that are desirable in the current market place.

The MNP platform, Intellectual Property (IP) assets and, a commercial product Estrasorb [transdermal estrogen] approved by the US FDA for menopausal women, were acquired from Novavax [NVAX- Nasdaq] in August 2010.